ATE264681T1 - Verbesserte arzneimittel - Google Patents

Verbesserte arzneimittel

Info

Publication number
ATE264681T1
ATE264681T1 AT97948461T AT97948461T ATE264681T1 AT E264681 T1 ATE264681 T1 AT E264681T1 AT 97948461 T AT97948461 T AT 97948461T AT 97948461 T AT97948461 T AT 97948461T AT E264681 T1 ATE264681 T1 AT E264681T1
Authority
AT
Austria
Prior art keywords
improved
resuspendability
improved medications
suspensions
medications
Prior art date
Application number
AT97948461T
Other languages
English (en)
Inventor
Todd P Foster
David L Kiefer
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE264681(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE264681T1 publication Critical patent/ATE264681T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97948461T 1996-12-09 1997-12-03 Verbesserte arzneimittel ATE264681T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions
PCT/US1997/021401 WO1998025621A1 (en) 1996-12-09 1997-12-03 Improved pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE264681T1 true ATE264681T1 (de) 2004-05-15

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948461T ATE264681T1 (de) 1996-12-09 1997-12-03 Verbesserte arzneimittel

Country Status (22)

Country Link
US (1) US5736151A (de)
EP (1) EP0941095B1 (de)
JP (1) JP2001505910A (de)
KR (1) KR100544248B1 (de)
CN (1) CN100413506C (de)
AT (1) ATE264681T1 (de)
AU (1) AU746666B2 (de)
BR (1) BR9714967B1 (de)
CA (1) CA2269682C (de)
CZ (1) CZ297632B6 (de)
DE (1) DE69728783T2 (de)
DK (1) DK0941095T3 (de)
ES (1) ES2218705T3 (de)
FI (1) FI991302A (de)
HK (1) HK1023292A1 (de)
HU (1) HUP0000564A3 (de)
NO (1) NO325475B1 (de)
NZ (1) NZ336183A (de)
PL (1) PL190662B1 (de)
PT (1) PT941095E (de)
SK (1) SK72399A3 (de)
WO (1) WO1998025621A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
EP1317256B1 (de) * 2000-09-12 2008-10-29 Pharmacia & Upjohn Company LLC Pharmazeutische zusammensetzung mit modifiziertem träger
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
AU2002328168B2 (en) * 2002-08-07 2008-08-21 Merial Ltd. Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
DK1608407T3 (da) * 2003-03-20 2006-12-04 Pharmacia Corp Dispergébar formulering af et antiinflammatorisk middel
RU2329064C2 (ru) * 2003-07-31 2008-07-20 Фармация Энд Апджон Компани Ллс Диспергируемая фармацевтическая композиция для лечения мастита и поражений уха
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
US8309138B2 (en) 2007-02-16 2012-11-13 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
WO2010059717A2 (en) 2008-11-19 2010-05-27 Merial Limited Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
SI2874624T1 (sl) 2012-07-17 2020-02-28 Bayer New Zealand Limited Formulacije antibiotikov za injektiranje in postopek njihove uporabe
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2018071810A1 (en) * 2016-10-13 2018-04-19 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
NL260648A (de) * 1961-01-31
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
JPH0749432B2 (ja) * 1985-08-12 1995-05-31 ジ・アップジョン・カンパニ− セファロスポリンハロゲン化水素酸塩のアルカリ金属塩への変換
JP2703964B2 (ja) * 1987-11-10 1998-01-26 ジ・アップジョン・カンパニー セファロスポリン抗生物質類
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
EP0477289A4 (en) * 1989-06-13 1992-07-22 Abbott Laboratories Anhydrous oil-based liquid suspension for delivering a medicament
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje

Also Published As

Publication number Publication date
AU5452998A (en) 1998-07-03
CZ297632B6 (cs) 2007-02-14
WO1998025621A1 (en) 1998-06-18
EP0941095B1 (de) 2004-04-21
PL190662B1 (pl) 2005-12-30
NO992780D0 (no) 1999-06-08
KR20000069360A (ko) 2000-11-25
HUP0000564A2 (hu) 2000-10-28
CA2269682A1 (en) 1998-06-18
FI991302A0 (fi) 1999-06-08
FI991302A (fi) 1999-06-08
ES2218705T3 (es) 2004-11-16
CZ202599A3 (cs) 1999-09-15
JP2001505910A (ja) 2001-05-08
CN100413506C (zh) 2008-08-27
SK72399A3 (en) 2000-05-16
US5736151A (en) 1998-04-07
BR9714967B1 (pt) 2010-06-29
KR100544248B1 (ko) 2006-01-23
CA2269682C (en) 2009-04-14
DK0941095T3 (da) 2004-08-02
DE69728783T2 (de) 2005-03-31
NO992780L (no) 1999-06-08
NO325475B1 (no) 2008-05-13
DE69728783D1 (de) 2004-05-27
NZ336183A (en) 2000-12-22
EP0941095A1 (de) 1999-09-15
HK1023292A1 (en) 2000-09-08
PT941095E (pt) 2004-08-31
HUP0000564A3 (en) 2001-01-29
CN1238690A (zh) 1999-12-15
AU746666B2 (en) 2002-05-02
BR9714967A (pt) 2001-10-30

Similar Documents

Publication Publication Date Title
ATE264681T1 (de) Verbesserte arzneimittel
IL149163A0 (en) Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them
DK0646115T3 (da) Heterocykliske/cykliske aminderivater
DE69617273D1 (de) Heterocyclisch substituierte cyclopentanderivate.
DK0830350T3 (da) Hidtil ukendte N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[B][1,5]diazepin-3-yl)acetamider
PA8486401A1 (es) Antibioticos cetolidos carbamato y carbazato
DE69626981D1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
DE69610628T2 (de) N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amide
CA2219359A1 (en) Hydantoin derivatives as intermediates for pharmaceutical active compounds
IT1277663B1 (it) Sospensioni acquose stabili di mesalazina per uso topico
DE69615155T2 (de) Basische oxazolinamid-derivate von ge2270 und ge2270-änlichen antibiotika
ATE236888T1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
ATE128122T1 (de) 9-substituierte bicyclo (3.3.0>octan-derivate verwendbar als txa2-antagonisten.
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их
FR2707496B1 (fr) Compositions pharmaceutiques antiradicalaires et/ou antilipoperoxydantes et/ou hépatotropes.
NO20010624D0 (no) N-substituerte azacykloheptanderivater, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0941095

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked